作 者丨孙永乐 编 辑丨陈思颖 3月11日，AI医疗概念人气高标塞力医疗（6 0 3 7 1 6 .SH），突然发布异动公告称，公司客户主 要为公立医院，受限于行业政策影响，以及应收账款回款不及预期，公司2 0 2 4年7月、8月和 2 0 2 5年1月 存在三笔合计4 . 6 8亿元募集资金到期未能及时归还的情形。 公告还显示，塞力医疗于2 0 2 4年3月2 5日收到中国证监会《立案告知书》，因公司涉嫌信息披 露违法违规，中国证监会决定对公司立案。公司尚未收到就立案调查事项的结论性意见或决 定。 南财快讯记者注意到，因"沾上"华为AI医疗概念，塞力医疗已连续两个交易日涨停。截至3月 1 2日收盘，报每股1 2 . 0 8元，总市值达2 3 . 0 7亿元。 | | 塞力医疗 603716 | 23 医药商业 -0.28% | | 同行对比 | | --- | --- | --- | --- | --- | | | 12.08 +1.10 +10.02% 積 | 溢价:转债 22.59% | | | | 委比 | +100.00% | 资金分析(万元) 76175 | | | | 5 | 1 | 主力流入: ...

最近有一件大事，可能会对我们国家全体打工人都产生决定性的影响，我不吊你们胃口，先说了，是大好事。 欧盟通过了《禁止强迫劳动法案》，去年底已经签署生效，但是有3年的过渡期： 这法案到底是干嘛的 呢？ 就是欧盟规定，如果企业 一旦强迫员工劳动， 那么 将禁止 进口 该产品到欧盟 。 注意，该法案非常严苛 ，比如你出口 一个空调，哪怕空调里 有一个 零件 强迫员工劳动也不行， 会 导致整台空调 被欧盟拒绝入关。 所以欧盟是怎么定义"强迫员工劳动"的呢？呵呵， 超时加班（每日>8小时、每周>40小时）即视为强迫劳动 ，"员工自愿"也不行。 写到这你们应该已经意识到，这个《禁止强迫劳动法案》会对我们打工人带来什么样的影响了，只要企业生产的产品还想出口到欧盟（未来很可能也包含 美国），他就必须严格落实员工每周工作低于40小时，否则生意就别做了。 因为某些原因，我们国家的《劳动法》长期无法落实，打工人的权益无法保障，好吧，现在轮到欧盟来整顿中国的用工市场了。 有用吗？当然，已经开始起效了。 上面的是海尔，美的最近也启动了针对性工时改革： 昨天我就在网上看到美的现在已经强制下班，18:20以后hr会催促所有员工离岗，不准"自 ...

Investment Rating - The report assigns an investment rating of "Recommended" for the pharmaceutical and biotechnology industry [3][33]. Core Insights - The "AI + Healthcare/Pharmaceutical" theme continues to gain traction, with short-term momentum expected to persist. The report highlights significant stock performance in the sector, with the pharmaceutical and biotechnology sector (SW) rising by 2.71%, outperforming the CSI 300 index, and all sub-sectors showing positive growth, particularly in medical services [3][4]. - In the U.S., Tempus AI, a representative company in medical AI, saw a weekly increase of approximately 30% and over 160% year-to-date, driving the momentum of the medical AI concept. In China, companies like KingMed Diagnostics and Dian Diagnostics announced collaborations with DeepSeek, indicating a shift towards the commercialization of AI applications in healthcare [4][3]. - The report emphasizes investment opportunities in sub-sectors such as "AI + Medical Imaging," "AI + Diagnostic Services," and "AI + Drug Development," recommending key companies including United Imaging, Mindray, BGI Genomics, and WuXi AppTec [3][4]. Industry Performance Tracking - The pharmaceutical and biotechnology sector (SW) rose by 2.71% in the week of February 10-14, ranking 5th among 31 Shenwan primary industries. The CSI 300 index increased by 1.19% during the same period [5][6]. - All sub-sectors experienced growth, with medical services leading at +6.51%, followed by medical devices at +4.81%, and pharmaceutical commerce at +4.18% [5][6]. - Notable individual stock performances included Dian Diagnostics (+46.29%), Mian Health (+31.58%), and United Imaging (+27.33%) [6]. Industry Dynamics and Key Company Tracking - The National Healthcare Security Administration released a list of key tasks for 2025, focusing on efficient medical insurance processes and direct settlements for collected drugs and consumables [7]. - The retail terminal drug sales scale in China is projected to reach 574 billion yuan in 2024, with a growth rate of 3.7%, indicating a slowdown in growth due to demographic and economic factors [8]. - The report also notes significant collaborations, such as Baiyang Pharmaceutical's agreement with Roche for the exclusive marketing rights of a targeted cancer drug in mainland China [9][11]. Industry Data Tracking - The report tracks various industry metrics, including the basic medical insurance fund income, which reached 28,507.29 billion yuan in 2024, showing a year-on-year growth of 5% [15][16]. - The domestic pharmaceutical manufacturing industry achieved a total revenue of 25,298.50 billion yuan in 2024, with profit totals declining by 1.1% year-on-year [17].

Investment Rating - The report assigns an investment rating of "Recommended" for the pharmaceutical and biotechnology industry [3][33]. Core Insights - The "AI + Healthcare/Pharmaceutical" theme continues to gain traction, with short-term momentum expected to persist. The domestic and international markets are witnessing significant developments in AI applications within healthcare, particularly with companies like Tempus AI showing substantial stock price increases [3][4]. - The report highlights investment opportunities in specific segments such as "AI + Medical Imaging," "AI + Diagnostic Services," and "AI + Drug Development," recommending key companies including United Imaging, Mindray, BGI, and WuXi AppTec [3][4]. Industry Performance Tracking - The pharmaceutical and biotechnology sector (SW) rose by 2.71% last week, outperforming the CSI 300 index, which increased by 1.19%. All sub-sectors within the industry experienced growth, with medical services leading at +6.51% [5][6]. - Notable individual stock performances included Dean Diagnostics (+46.29%) and Meinian Health (+31.58%), while stocks like Betta Pharmaceuticals saw declines of -11.36% [6]. Industry Dynamics and Key Company Tracking - The National Healthcare Security Administration released a list of key tasks for 2025, focusing on efficient medical insurance processes and direct settlements for collected drugs and consumables [7]. - Recent collaborations include Baiyang Pharmaceutical signing a commercialization agreement with Roche for the drug Rituximab, and Sanofi Biologics partnering with Baili Tianheng to explore new treatment potentials in oncology [11][12]. Industry Data Tracking - The retail terminal drug sales in China are projected to reach CNY 574 billion in 2024, with a growth rate of 3.7%, indicating a slowdown compared to previous years [8]. - The medical insurance fund's income for 2024 is reported at CNY 28,507.29 billion, reflecting a year-on-year growth of 5.00% [15][16]. - The domestic pharmaceutical manufacturing industry achieved a total revenue of CNY 25,298.50 billion in 2024, remaining stable compared to the previous year [17].

证券研究报告 | 行业周报 2025 年 03 月 02 日 医药 本周医药板块下跌 2.72%，礼来加强 IBD 赛道布局 | 股票 | 股票 | 投资 | EPS （元） | | PE | | | --- | --- | --- | --- | --- | --- | --- | | 代码 | 名称 | 评级 | 2024E | 2025E | 2024E | 2025E | | 002755.SZ | 奥赛康 | 买入 | 0.13 | 0.2 | 110.38 | 71.75 | | 01952.HK | 云顶新耀-B | 买入 | -2.93 | -0.12 | - | - | | 02105.HK | 来凯医药-B | 买入 | -0.9 | -1 | - | - | | 600079.SH | 人福医药 | 增持 | 1.33 | 1.59 | 14.95 | 12.51 | | 688192.SH | 迪哲医药 | 增持 | -2.01 | -1.33 | -23.91 | -36.13 | | 688315.SH | 诺禾致源 | 买入 | 0.47 | 0.53 | 36.68 | 32. ...

证券代码：002589 证券简称：瑞康医药 公告编号：2025-008 瑞康医药集团股份有限公司 估值提升计划 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、估值提升计划触及情形及审议程序 （一）触发情形 根据《上市公司监管指引第 10 号--市值管理》的规定，股票连续 12 个月每 个交易日收盘价均低于其最近一个会计年度经审计的每股归属于公司普通股股 东的净资产的上市公司(以下简称"长期破净公司")，应当制定上市公司估值提 升计划，并经董事会审议后披露。 自 2024 年 1 月 1 日至 2024 年 12 月 31 日，瑞康医药集团股份有限公司（以 下简称"公司"）股票已连续 12 个月每个交易日收盘价均低于最近一个会计年 度经审计的每股归属于公司普通股股东的净资产。公司于 2024 年 4 月 30 日披露 2023 年年度报告，2024 年 1 月 1 日至 2024 年 4 月 30 日前每个交易日股票收盘 价变动区间为 2.19 元/股-3.28 元/股，均低于 2022 年度经审计的每股净资产 3.59 元;2024 年 5 月 1 日至 20 ...

今天有一个里程碑式的事件，比特币的价格正式站上了10万美元。 其实半个多月前价格就已经来到97000附近，但随后在整数关口前进行了一段时间的调整，调整的这两个星期成了山寨币的窗口期，大量二线蓝筹蹦蹦跳 跳的完成了100-300%的涨幅。然后就是今天，带头大哥正式进入6位数时代。 多年前币圈曾经喊出过一个振聋发聩的口号，一币一墅，这在当时被当做是遥不可及的妄言妄语，但现如今已经摸得着边了，73万已经可以覆盖别墅的建 安成本，这一轮行情我觉得已经差不多了，等到4年后、8年后我们到时候再看看一个币能换到哪里的别墅。 今天刷到一个新闻，美图公司把持有的加密货币都卖了，盈利7900万美元，打算拿来给股东们特别分红。美团是2021年3月、4月入场的，btc和eth各买了 5000万美元，加起来1个亿。eth的成本是1600+，btc的成本是56000+。 其实这个btc买的不便宜，之后冲高到69000后开始回调，一度都跌到16000，美图浮亏严重。当时很多美图股东都在骂蔡文胜拿公司的钱瞎搞，不过在今 年又变成了"真香"。借着这波行情蔡文胜获利了结，最终盈利接近80%下车，浮盈不算赢，拿钱离场才是真赢。 我最近也开始止盈， ...

安徽华人健康医药股份有限公司 审计报告 中天运[2022]审字第 90416 号 中天运会计师事务所 (特殊普通合伙) JONTEN CERTIFIED PUBLIC ACCOUNTANTS LLP 3-2-1-1 19 2017, Regardland Counc als alled of the problem of the the comments of the comment of the may be 北京注册会计师协会 业务报告统一编码报备系统 | 业务报备统一编码: | 110002042022710007411 | | --- | --- | | 报告名称: | 2022 年 1-6 月华人健康审计报告 | | 报告文号: | 中天运[2022]审字第 90416 号 | | 被审(验)单位名称: | 安徽华人健康医药股份有限公司 | | 会计师事务所名称: | 中天运会计师事务所 | | 业务类型: | 财务报表审计 | | 报告意见类型: | 无保留意见 | | 报告日期: | 2022 年 09月 13 日 | | 报备日期: | 2022 年 09 月 07 日 | | | 陈晓龙(3 ...